This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bionomics 過去の業績

過去基準チェック /06

Bionomicsの収益は年間平均-3.4%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間7.7% 42.6%割合で減少しています。

主要情報

-3.4%

収益成長率

27.8%

EPS成長率

Biotechs 業界の成長	-14.6%
収益成長率	-42.6%
株主資本利益率	-52.2%
ネット・マージン	-413.9%
前回の決算情報	31 Dec 2022

Recent updates

収支内訳

Bionomics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

DB:B1N 収益、費用、利益 ( )AUD Millions
日付	収益	収益	G+A経費
31 Dec 22	6	-25	7
30 Sep 22	6	-23	7
30 Jun 22	6	-22	8
31 Mar 22	3	-22	8
31 Dec 21	0	-22	8
30 Sep 21	1	-15	7
30 Jun 21	1	-9	6
31 Mar 21	1	-4	5
31 Dec 20	2	1	5
30 Sep 20	2	-3	5
30 Jun 20	3	-6	5
31 Dec 19	6	-5	5
30 Sep 19	7	-8	6
30 Jun 19	7	-10	8
31 Mar 19	8	-20	11
31 Dec 18	8	-28	11
30 Sep 18	10	-27	11
30 Jun 18	12	-25	11
31 Mar 18	19	-15	9
31 Dec 17	27	-6	8
30 Sep 17	27	-6	8
30 Jun 17	27	-7	8
31 Mar 17	22	-12	10
31 Dec 16	16	-17	12
30 Sep 16	18	-17	11
30 Jun 16	19	-17	11
31 Mar 16	19	-19	10
31 Dec 15	18	-21	9
30 Sep 15	17	-19	9
30 Jun 15	15	-17	9
31 Mar 15	22	-6	7
31 Dec 14	29	4	5
30 Sep 14	28	4	5
30 Jun 14	27	3	5
31 Mar 14	19	-5	5
31 Dec 13	12	-13	5
30 Sep 13	12	-11	5
30 Jun 13	12	-10	5
31 Mar 13	13	-7	5
31 Dec 12	13	-4	4
30 Sep 12	12	-3	4

質の高い収益: B1Nは現在利益が出ていません。

利益率の向上: B1Nは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: B1Nは利益が出ておらず、過去 5 年間で損失は年間3.4%の割合で増加しています。

成長の加速: B1Nの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: B1Nは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -18.2% ) と比較することは困難です。

株主資本利益率

高いROE: B1Nは現在利益が出ていないため、自己資本利益率 ( -52.21% ) はマイナスです。

This company listing is no longer active

Bionomics 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

Full year 2022 earnings released: AU$0.016 loss per share (vs AU$0.011 loss in FY 2021)

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Full year earnings released - €0.0082 loss per share

Recent updates

New minor risk - Financial data availability

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

New major risk - Market cap size

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

High number of new directors

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: AU$0.016 loss per share (vs AU$0.011 loss in FY 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

High number of new directors

U.S. Food and Drug Administration Grants Bionomics Fast Track Designation to Bnc210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Bionomics Initiates Phase 2B ATTUNE Study of BNC210 in PTSD

Bionomics BNC210 Expansion into Social Anxiety Disorder

Legal Counsel & Company Secretary has left the company

Revenue beats expectations

Bionomics Limited has completed a Follow-on Equity Offering in the amount of AUD 15.991634 million.

Bionomics Limited Announces Positive BNC210 PK Results for Solid Dose Formulation

New 90-day high: €0.27

Bionomics Limited and EmpathBio Inc Joint Feasibility Assessment

Bionomics Limited announced that it expects to receive AUD 15.991634 million in funding

Bionomics Limited Completes Treatment Phase in the MODULATE Clinical Trial

Bionomics Limited Announces Publication of Positive BNC210 Phase 2a Data in Gad Patients

Bionomics Limited Initiates 7-Day Dosing Pharmacokinetic Study of BNC210

Bionomics Limited Licenses Drug Candidate BNC101 to Carina Biotech

Bionomics Limited Announces Director Changes

Bionomics Limited announced that it has received AUD 5.43332 million in funding from Apeiron Investment Group Ltd. and other investors

Full year earnings released - €0.0082 loss per share

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06